A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs MEDI 5083 (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 17 Apr 2017 Planned End Date changed from 1 Sep 2022 to 15 Aug 2022.
- 17 Apr 2017 Planned primary completion date changed from 1 Sep 2022 to 15 Aug 2022.
- 17 Apr 2017 Status changed from not yet recruiting to recruiting.